Tackling the MARCKS-PIP3 Circuit to Attenuate Chronic Pulmonary Fibrosis

解决 MARCKS-PIP3 回路以减轻慢性肺纤维化

基本信息

  • 批准号:
    10152291
  • 负责人:
  • 金额:
    $ 34.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary Lung fibrosis is an important step of normal lung injury-repair process. However, uncontrolled injury and repair, and excessive deposition of collagen in the lung parenchyma is the pathological hallmark of chronic pulmonary fibrosis, such as idiopathic pulmonary fibrosis (IPF). The disease exhibits a median survival time of only 3 to 5 years from the time of diagnosis. Currently, there is no suitable drug for the treatment, except two drugs: Nintedanib and Pirfenidone, approved by FDA. However, adverse and off-target effects, and failure to demonstrate increased longevity in treated patients indicate the urgent need for new and better therapeutic agent(s) to treat this devastating disease. Epithelial-mesenchymal (EM) and fibroblast-myofibroblast (FM) transitions have been implicated in the initiation and the progression of fibrotic lung pathogenesis. The EM and FM transition phenomena, important pathogenic events associated with cancer malignancy, are primordially and mainly mediated by receptor-mediated tyrosine kinase (RTK) and PI3K-AKT signaling pathways. We have shown before the elevation of phospho-MARCKS in lung cancer tissues/cells associated with EM transition and the use of a peptide inhibitor, MPS (MARCKS PSD/ED Sequence), to suppress EM transition and lung cancer malignancy through tackling the aberrant MARCKS-PIP3 circuit associated with cancer pathogenesis. The elevated phospho-MARCKS phenomenon is also seen in tissue sections and isolated fibroblasts derived from IPF lungs, but not seen in any normal, non-fiberotic ones. Our recent publication had shown the therapeutic potential of MPS peptide in the suppression of the fibrotic lesions in bleomycin-induced fibrotic mouse lungs. In vitro, MPS tackles the aberrant MARCKS-PIP3 circuit to suppress MARCKS phosphorylation and also selectively inhibits the EM/FM transition and myofibroblast fibrogenesis, as well as the alteration of M1/M2 macrophage polarization. The selectivity occurs only on IPF-derived fibroblasts and activated macrophage, but not on the normal and inactivated monocytes. Through peptide optimization, we have developed further a stable, more biosafe, and high potency of a novel MPS-derived peptide, MPS-6413DTM. Initial studies have shown the efficacy of this peptide on the suppression of bleomycin-induced lung fibrotic lesions and deceased in mice, but not on the control ones. We hypothesize that MPS-6413D is a potent anti-fibrotic lung drug on the inhibition of fibrogenic progression of chronic lung fibrosis through tackling the MARCKS-PIP3 circuit. To test this hypothesis and the therapeutic potential of this peptide, two aims are proposed. Aim 1 is to determine further the therapeutic effects of MPS-6413D peptide on bleomycin induced lung fibrotic lesions in aged 32-week old (equivalent to 42 years old human) mice. The therapeutic potency will be determined on the inhibition of the expression of profibrogenic marker proteins and their RNA, and the inhibition of MARCKS and its phosphorylation in total lung homogenates, matrix deposition, pulmonary function, and also the overall survival and well-being in these age mice after bleomycin exposure. Aim 2 is to evaluate an inhibitory effect of MPS-6413D peptide on fibrogenic activity of IPF lung fibroblasts in humanized mouse model. To better reflect clinical scenarios, IPF human lung fibroblasts (HLFs) will be adoptively transferred to C.B-17 SCID/bg mice in order to test the therapeutic potential of MPS in lung fibrosis. Success of these studies will lead to the submission of the Phase II SBIR study on animals with spontaneous lung fibrosis, the pharmacodynamic/pharmacokinetic analysis, an IND-based study to FDA for future clinical drug development to attenuate chronic pulmonary fibrosis.
项目摘要 肺纤维化是正常肺损伤修复过程中的重要环节。然而,不受控制的损伤和修复, 肺实质胶原过度沉积是慢性肺纤维化的病理标志 肺纤维化,例如特发性肺纤维化(IPF)。这种疾病的平均生存时间只有3到5年 从诊断之日起的几年内。目前,除了两种药物外,没有合适的药物用于治疗: FDA批准的Nepal和吡非尼酮。然而,不良和脱靶效应,以及未能 治疗患者寿命延长表明迫切需要新的和更好的治疗方法, 治疗这种毁灭性疾病的药物。上皮-间充质(EM)和成纤维细胞-肌成纤维细胞(FM) 这些转变与肺纤维化发病机制的发生和发展有关。EM和 FM转换现象是与癌症恶性相关的重要致病事件, 主要由受体介导的酪氨酸激酶(RTK)和PI 3 K-AKT信号通路介导。我们已经表明 在与EM转变相关的肺癌组织/细胞中磷酸-MARCKS升高之前, 肽抑制剂MPS(MARCKS PSD/艾德序列)抑制EM转换和肺癌 通过解决与癌症发病机制相关的异常MARCKS-PIP 3回路来治疗恶性肿瘤。的 在组织切片中也观察到升高的磷酸-MARCKS现象,并且分离的成纤维细胞来源于 IPF肺,但在任何正常、非纤维化肺中未见。我们最近的出版物表明了治疗作用 MPS肽在博来霉素诱导的纤维化小鼠肺中抑制纤维化病变的潜力。在 在体外,MPS处理异常MARCKS-PIP 3回路以抑制MARCKS磷酸化,并且还选择性地 抑制EM/FM转变和肌成纤维细胞纤维化,以及M1/M2巨噬细胞的改变 极化选择性只发生在IPF衍生的成纤维细胞和活化的巨噬细胞上,而不发生在 正常和失活的单核细胞。通过肽优化,我们进一步开发了一种稳定的, 生物安全性和高效力的新型MPS衍生肽MPS-6413 DTM。初步研究表明, 这种肽的抑制博莱霉素诱导的肺纤维化病变和死亡的小鼠,但没有 对照组我们假设MPS-6413 D是一种有效的抗肺纤维化药物,可抑制纤维化。 通过处理MARCKS-PIP 3回路来控制慢性肺纤维化的进展。为了验证这一假设, 这种肽的治疗潜力,提出了两个目标。目的1是进一步确定治疗效果 MPS-6413 D肽对32周龄(相当于42岁)博莱霉素诱导的肺纤维化病变的作用 老年人)小鼠。治疗效力将根据对促纤维化蛋白表达的抑制来确定。 标记蛋白及其RNA,以及MARCKS的抑制及其在总肺匀浆中的磷酸化, 基质沉积,肺功能,以及这些年龄小鼠的总体存活率和健康状况, 博莱霉素暴露。目的2是评价MPS-6413 D肽对IPF纤维化活性的抑制作用 人源化小鼠模型中的肺成纤维细胞。为了更好地反映临床情况,IPF人肺成纤维细胞 (HLF)将过继转移到C.B-17 SCID/bg小鼠中,以测试MPS在小鼠中的治疗潜力 肺纤维化这些研究的成功将导致提交关于动物的II期SBIR研究, 自发性肺纤维化,药效学/药代动力学分析,向FDA提交的基于IND的研究, 未来的临床药物开发,以减轻慢性肺纤维化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Reen Wu其他文献

Reen Wu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Reen Wu', 18)}}的其他基金

Novel antimicrobials in fighting carbapenem-resistant Klebsiella pneumoniae
对抗耐碳青霉烯类肺炎克雷伯菌的新型抗菌药物
  • 批准号:
    10602594
  • 财政年份:
    2022
  • 资助金额:
    $ 34.77万
  • 项目类别:
PLASTICITY OF NON HUMAN PRIMATE TH17 CELL DIFFERENTIATION IN VITRO
非人灵长类 TH17 细胞体外分化的可塑性
  • 批准号:
    8357347
  • 财政年份:
    2011
  • 资助金额:
    $ 34.77万
  • 项目类别:
Regulation of Airway Mucin Gene Expression by Epigenetic Mechanism
表观遗传机制对气道粘蛋白基因表达的调控
  • 批准号:
    8247005
  • 财政年份:
    2010
  • 资助金额:
    $ 34.77万
  • 项目类别:
Regulation of Airway Mucin Gene Expression by Epigenetic Mechanism
表观遗传机制对气道粘蛋白基因表达的调控
  • 批准号:
    8451277
  • 财政年份:
    2010
  • 资助金额:
    $ 34.77万
  • 项目类别:
PLASTICITY OF NON HUMAN PRIMATE TH17 CELL DIFFERENTIATION IN VITRO
非人灵长类 TH17 细胞体外分化的可塑性
  • 批准号:
    8172630
  • 财政年份:
    2010
  • 资助金额:
    $ 34.77万
  • 项目类别:
Regulation of Airway Mucin Gene Expression by Epigenetic Mechanism
表观遗传机制对气道粘蛋白基因表达的调控
  • 批准号:
    8050564
  • 财政年份:
    2010
  • 资助金额:
    $ 34.77万
  • 项目类别:
Regulation of Airway Mucin Gene Expression by Epigenetic Mechanism
表观遗传机制对气道粘蛋白基因表达的调控
  • 批准号:
    7918317
  • 财政年份:
    2010
  • 资助金额:
    $ 34.77万
  • 项目类别:
Regenerative Airway Epithelium by Embryonic Stem Cells
胚胎干细胞再生气道上皮
  • 批准号:
    7187990
  • 财政年份:
    2007
  • 资助金额:
    $ 34.77万
  • 项目类别:
Regenerative Airway Epithelium by Embryonic Stem Cells
胚胎干细胞再生气道上皮
  • 批准号:
    7342093
  • 财政年份:
    2007
  • 资助金额:
    $ 34.77万
  • 项目类别:
Project 2 - Postnatal Development of Pulmonary Immune Mechanisms
项目2——产后肺部免疫机制的发育
  • 批准号:
    7089293
  • 财政年份:
    2006
  • 资助金额:
    $ 34.77万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 34.77万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 34.77万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 34.77万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 34.77万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 34.77万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 34.77万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 34.77万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 34.77万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 34.77万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 34.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了